

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Material

Supplemental Table 1: Combined causes or precipitating factors (such as infections, transplantations, drugs and malignancies) in TMA

Supplemental Figure 1: Admission of patients with TMAs to medical and surgical units

Supplemental Figure 2: Incidence of primary and secondary TMAs

Supplement Table: Combined causes or precipitating factors (such as infections, transplantations, drugs and malignancies) in TMA


		Primary TMA				Secondary TMA						
		All n=562	TTP n=18	aHUS n=15	Shiga toxin E.Coli n=33	Pregnancy n=197	Auto-immune n=48	Malignant HT n=20	Infection n=105	Transplantation n=184	Drug n=96	Other TMAs n=31
Only cause	%	51	61	67	100	90	45	55	17	50	0	100
Presence of:												
<i>Infection</i>	%	33	39	20	0	8	45	40	49	-	54	49
<i>Drug</i>	%	25	6	33	0	2	20	30	62	39	97	-
<i>Malignancy</i>	%	18	11	7	0	1	10	10	-	28	32	44
<i>Transplantation</i>	%	17	0	33	0	1	12	25	30	28	-	65

Number of additional causes or precipitating factors (such as infections, transplantations, drugs and malignancies)												
<i>1 cause</i>	%	21	28	0	0	9	33	15	41	16	33	40
<i>2 causes</i>	%	14	6	13	0	1	12	10	25	26	49	42
<i>3 causes</i>	%	11	6	13	0	0	10	10	16	9	18	12
<i>4 causes</i>	%	3	0	7	0	0	0	10	-	-	-	0

Of note, 2/564 patients had missing values
TMA: thrombotic microangiopathy; aHUS: atypical hemolytic uremic syndrome; HT: hypertension; TTP: thrombotic thrombocytopenic purpura

Supplemental Figure 1: Admission of patients with TMAs to medical and surgical units

Other units: infectious diseases (2%), cardiology (1%), pneumology (1%), rheumatology (0.9%), neurology (0.5%), dermatology (0.5%), and geriatrics (0.5%).



Supplemental Figure 2: Incidence of primary and secondary TMAs

Incidence of TMA in relation to the cause: TTP, aHUS, HUS due to E.Coli shiga toxin, infections, auto-immune diseases, malignant hypertension, malignancies, drugs, transplantations and other secondary TMAs.

